8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis
Status:
Completed
Trial end date:
2018-09-19
Target enrollment:
Participant gender:
Summary
Grazoprevir plus elbasvir 12 to 16 weeks is now approved for chronic hepatitis C (CHC)
genotype 1, 4, or 6 infection regardless liver disease severity. The current study aims to
explore the efficacy and safety of 8-week grazoprevir/elbasvir in HCV-1b patients with mild
liver fibrosis
Phase:
Phase 3
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital